Connect with us

Headlines

Optical Product Firm Looks North to a Whole New Market

It will distribute contact lenses in Canada.

mm

Published

on

CORAL SPRINGS, FL – ABB Optical Group, a provider of optical products and business solutions in the eyecare industry, announced its expansion into the Canadian market.

Beginning in 2020, ABB Optical will distribute contact lenses in Canada, starting with servicing FYidoctors, Canada’s largest doctor-owned provider of eyecare and ophthalmic products and services, and Independent Alliance clinics.

The company stated in a press release: “According to ABB OPTICAL’s market intelligence, eye care professionals in Canada have not had the opportunity to benefit from contact lens consolidation and business management best practices with one distributor – a common model in the United States which provides efficiency, cost savings, and better, faster service for practices and patients.”

“We are excited about our expansion into the Canadian market and look forward to serving the country’s eye care professionals,” said ABB Optical CEO Tom Burke. “We have seen time and time again that efficient contact lens supply chain management can help improve patient care. Benefits to a practice include lowered costs, administrative time savings and improved turn-around time for patients to receive their lenses.”

Burke added that ABB Optical’s expansion into Canada also benefits the Canadian economy, stating, “In addition to servicing eye care professionals, we’re excited to be making a substantial economic investment in Canada. ABB OPTICAL will operate its own Canadian distribution center which will house inventory, and our expanded business will provide job opportunities for Canadians.”

FYidoctors’ CEO and Chairman Dr. Alan Ulsifer said, “ABB’s entrance into Canada will bring incredible benefits to Canadian optometrists. The company’s proven systems of single source ordering, direct to patient delivery, and business solutions and services will help Canadian optometrists thrive in a market that continues to be challenging. We are very excited and proud to be their first customers.”

Advertisement

ABB Optical noted that it “also offers other business solutions for the optical industry that could benefit Canadian eye care professionals in the future, such as lens fabrication, ophthalmic lens distribution, frames distribution, practice development strategies, a data and analytics platform, and gas permeable contact lens manufacturing.”

Advertisement

SPONSORED VIDEO

SPONSORED BY REICHERT

When You’re Passionate About Eye Care, the Right Technology Matters

Lisa Genovese, O.D., strives to give her patients the very best. At Insight Eye Care’s multiple locations, Dr. Genovese provides optimal care for her patients using the Reichert® Phoroptor® VRx Digital Refraction System. In this second Practice Profile Video from Reichert’s “Passionate About Eye Care” series, take a closer look and see how this eye care professional achieved a better work-life balance with equipment that’s designed and engineered in the U.S.A.

Promoted Headlines

Headlines

Idaho Considers Allowing ODs to Perform Laser Eye Surgery

But the bill has drawn opposition from some ophthalmologists.

mm

Published

on

Proposed legislation in Idaho would give optometrists the right to perform laser eye surgery.

In order to perform laser procedures, optometrists would have to pass an examination by the National Board of Examiners in Optometry, East Idaho News reports. They they would be required to do at least five of the procedures under supervision of an ophthalmologist.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The proposal is a House bill supported by The Idaho Bureau of Occupational Licensing. It’s currently being discussed in the House Health & Welfare Committee.

“We want to make sure that our laws and rules are as up to date as possible,” said Julie Eavenson of the Idaho Bureau of Occupational Licensing, according to East Idaho News.

“And the reason that we’re looking at them is because the governor has said — and the Legislature — ‘You need to have minimum qualifications. You need to protect the public, but you need to remove barriers.'”

The bill has drawn opposition from some ophthalmologists.

The legislation “poses an incredible risk to Idahoans and ignores the importance of medical education and training to perform surgery,” Dr. James Earl of Retina Specialists of Idaho said in a press release issued by from Eye M.D.s of Idaho.

The issue has been hotly debated in other states.

Advertisement

In March, the governor of Arkansas signed into law a measure allowing optometrists to perform certain surgical procedures. The operations included selective laser trabeculoplasty and Nd:YAG laser procedures, along with injections (excluding intravenous and intraocular), removal of lid lesions and chalazion incision and curettage.

At the time, the American Optometric Association stated that Arkansas was the fourth state to permit laser procedures and that Alaska was developing regulations for their use.

Read more at the East Idaho News

Continue Reading

Headlines

AOA Approved for Group Purchasing of Lenses, Frames, Contacts

The U.S. Department of Justice gave its OK.

mm

Published

on

The U.S. Department of Justice has given the American Optometric Association the nod to expand its group purchasing activities to include lenses, frames and contacts.

The association and its subsidiary AOAExcel GPO LLC had asked the department for a business review letter on the matter. Law360 explains that such a document can provide “proactive assurances of non-enforcement.”

The department explained in the Jan. 15 letter that it “presently does not intend to challenge the GPO’s expansion to include optometric products.” It noted, however, that it “reserves the right to challenge the GPO in the future if the GPO’s operations are determined to be anticompetitive in purpose or effect.”

Up until now, AOA’s group purchasing organization has only offered non-optometric products, such as professional liability insurance, credit card processing, life insurance, general office supplies, general medical supplies and equipment. It uses Intalere, a third-party healthcare group purchasing organization, as its agent to negotiate discounts on products and services.

Advertisement

As of February 2019, 1,011 association member optometric practices had signed up to participate, and 251 practices had made at least one purchase.

The Department of Justice wrote: “Based on our investigation and your representations described above regarding the GPO [group purchasing organization] and its proposed expansion to include optometric products, the GPO expansion is unlikely to produce anticompetitive effects.”

Continue Reading

Headlines

Biotech Firm Raises $30M for Eye Disease Therapies

It’s focusing on retinal and other ophthalmic maladies.

mm

Published

on

PARIS & FORT WORTH, TX — Eyevensys, a biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases, has completed a $30 million funding round.

The company will use the funds to continue development of its clinical lead candidate — known as EYS606 — for the treatment of chronic non-infectious uveitis, including the launch of its Electro Study, according to a press release. This Phase 2 trial, to be conducted in the U.S., will evaluate the safety and efficacy of the candidate in patients with active forms of all anatomic uveitis subtypes.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The funding will also advance the preclinical development of the firm’s other therapeutic proteins targeting ophthalmic diseases with unaddressed medical needs, such as retinitis pigmentosa and age-related macular degeneration. A product candidate known as EYS606 is currently in a phase I/II clinical trial in the European Union and has been granted an Orphan drug designation by the European Medicines Agency for the treatment of non-infectious uveitis.

The new Series B financing round was led by Boehringer Ingelheim Venture Fund and included participation from existing investors Pontifax, Bpifrance, CapDecisif, and Inserm Transfert, as well as new investors, the Global Health Sciences Fund (Quark Venture LP and GF Securities) and Pureos Bioventures.

In conjunction with the financing, Eyevensys has added members to its board of directors. Neena Kadaba, PhD, director of science at Quark Venture LP, joined the board, as did Dominik Escher, PhD, managing partner at Pureos Bioventures and former founder and CEO of ESBATech, an ophthalmology biotech company acquired by Alcon in 2009.

Eyevensys has also recently opened a wholly owned U.S. subsidiary in Fort Worth, TX. All U.S. operations will be managed from this location, though the Eyevensys headquarters will remain in Paris.

Dr. Patricia Zilliox, Chief Executive Officer, said, “We are thrilled to have completed this Series B funding round with the strong support from both existing and new investors for the company. This funding will assist the further development of our technology and position Eyevensys as an innovator in the field of ophthalmology.”

She continued: “As we launch the Electro Study, our first U.S. clinical trial, Eyevensys will also have an opportunity to connect with ophthalmology opinion leaders in the U.S. to gain further exposure for our groundbreaking technology platform. This will also move the company one step closer to providing a more effective and convenient treatment approach to ease the burden of managing patients with chronic ocular conditions.”

As for technical specifics, the company states:

The Eyevensys technology is a non-viral gene therapy ocular drug delivery platform that uses an Electrotransfection System to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle. This turns the eye into a biofactory, allowing the ciliary muscle to express and secrete the therapeutic protein to the back of the eye at therapeutic levels for a duration of greater than 6 months.

Continue Reading

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular